

1 **Title: Enhanced differentiation of IgA<sup>+</sup> class-switched CD27<sup>+</sup>CD21<sup>+</sup> B cells in**  
2 **patients with IgA nephropathy**

3

4 **Authors:**

5 Anna Popova<sup>1,2,3†</sup>, Baiba Slisere<sup>4,5†</sup>, Karlis Racenis<sup>1,2,6†</sup>, Viktorija Kuzema<sup>1,6†</sup>, Roberts  
6 Karklins<sup>6</sup>, Mikus Saulite<sup>1,6</sup>, Janis Seilis<sup>1</sup>, Anna Jana Saulite<sup>1</sup>, Aiga Vasilvolfa<sup>1,3,6</sup>,  
7 Kristine Vaivode<sup>7</sup>, Dace Pjanova<sup>7</sup>, Juta Kroica<sup>2</sup>, Harijs Cernevskis<sup>1,6</sup>, Aivars  
8 Lejnicks<sup>6,8</sup>, Aivars Petersons<sup>1,6</sup>, Kristine Oleinika<sup>6,9\*</sup>

9

10 **Affiliations:**

11 1 Department of Nephrology, Pauls Stradins Clinical University Hospital, Riga, Latvia

12 2 Department of Biology and Microbiology, Riga Stradins University, Riga, Latvia

13 3 Department of Internal Medicine, University of Latvia, Riga, Latvia

14 4 Joint Laboratory, Pauls Stradins Clinical University Hospital, Riga, Latvia

15 5 Department of Doctoral Studies, Riga Stradins University, Riga, Latvia

16 6 Department of Internal Diseases, Riga Stradins University, Riga, Latvia

17 7 Institute of Microbiology and Virology, Riga Stradins University, Riga, Latvia

18 8 Riga East Clinical University Hospital, Riga, Latvia

19 9 Program in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard  
20 Medical

21 School, Boston, MA, USA

22 † These authors contributed equally

23 Correspondence to: [Kristine.Oleinika@rsu.lv](mailto:Kristine.Oleinika@rsu.lv)

24

25 **Word count** (maximum 3500): 3500

26 **Number of figures, tables, boxes, references:** 5 figures, 1 table, 47 references.

27 **Running head:** Mechanisms of IgA<sup>+</sup> B cell differentiation in IgAN

1 **Abstract**

2 Background: IgA nephropathy (IgAN) is characterised by the production of galactose-  
3 deficient IgA1 (Gd-IgA1) antibodies. As the source of pathogenic antibodies, B cells  
4 are central to IgAN pathogenesis, but the B cell activation pathways as well as the  
5 potential B cell source of dysregulated IgA-secretion remain unknown.

6 Methods: We carried out flow cytometry analysis of peripheral blood B cells in patients  
7 with IgA nephropathy and control subjects with a focus on IgA-expressing B cells to  
8 uncover the pathways of B cell activation in IgAN and how these could give rise to  
9 pathogenic GdIgA1 antibodies.

10 Results: In addition to global changes in the B cell landscape – expansion of naive and  
11 reduction in memory B cells – IgAN patients present with an increased frequency of  
12 IgA-expressing B cells that lack the classical memory marker CD27, but are CD21<sup>pos</sup>.  
13 IgAN patients further have an expanded population of IgA<sup>pos</sup> antibody-secreting cells,  
14 which correlate with serum IgA levels. Both IgA<sup>pos</sup> plasmablasts and CD27<sup>neg</sup> B cells  
15 co-express GdIgA1. Implicating dysregulation at mucosal surfaces as the driver of  
16 such B cell differentiation, we found a correlation between lipopolysaccharide (LPS) in  
17 the serum and IgA<sup>pos</sup>CD27<sup>neg</sup> B cell frequency.

18 Conclusion: We propose that dysregulated immunity in the mucosa may drive-de novo  
19 B cell activation within germinal centres, giving rise to IgA<sup>pos</sup>CD27<sup>neg</sup> B cells and  
20 subsequently IgA-producing plasmablasts. These data integrate B cells into the  
21 paradigm of IgAN pathogenesis and allow to further investigate this pathway to  
22 uncover biomarkers and develop therapeutic interventions.

23  
24  
25  
26  
27  
28  
29  
30  
31

## 1 **Key learning points**

### 2 **What was known:**

- 3 • Patients with IgA nephropathy (IgAN) have aberrant production of galactose-  
4 deficient IgA1 (Gd-IgA1) and antibodies against it, which together form immune  
5 complexes that are deposited in the renal mesangium and lead to kidney  
6 damage; this is known as the multi-hit model of IgAN pathogenesis.
- 7 • The multi-hit model centrally implicates B cells as they produce both Gd-IgA1  
8 and antibodies against it, yet B cell activation pathways that lead to aberrant  
9 antibody production are absent from the model.
- 10 • Only isolated reports exist describing specific features of B cells that are altered  
11 in patients with IgAN, including a reduction in regulatory B cells, increase in toll-  
12 like receptor 7 expression in total peripheral blood B cells and elevated  
13 frequency of circulating CCR9<sup>+</sup>IgA<sup>+</sup> B cells.

### 14 **This study adds:**

- 15 • In addition to changes in the overall circulating B cell landscape, differentiation  
16 of IgA<sup>+</sup> plasmablasts is enhanced in patients with IgAN and their levels correlate  
17 with serum IgA.
- 18 • IgA-expressing plasmablast frequency correlates with that of IgA<sup>+</sup>CD21<sup>+</sup> B cells,  
19 that lack the classical memory B cell marker CD27.
- 20 • Both IgA<sup>+</sup> plasmablasts and IgA-expressing CD27<sup>-</sup> B cells co-express GdIgA1  
21 receptors.
- 22 • IgA<sup>+</sup>CD27<sup>-</sup>CD21<sup>+</sup> B cell frequency correlates with serum lipopolysaccharide  
23 (LPS) levels, implicating mucosa in their activation.

### 24 **Potential impact:**

- 25 • We uncover the previously unknown B cell activation pathway that appears to  
26 be associated with pathogenic IgA secretion in IgAN and integrate this into the  
27 multi-hit model of IgAN pathogenesis.
- 28 • This pathway holds potential for further investigation to identify biomarkers and  
29 therapeutic targets in IgAN.

30

31 **Keywords:** B cells, IgA nephropathy, IgA-producing plasmablasts, antibodies, disease  
32 mechanisms

## 1 Introduction

2 IgA nephropathy (IgAN) is an autoimmune disease and the most common form of  
3 primary glomerulonephritis with an estimated global incidence of at least 2.5 cases per  
4 100'000 adults annually (1). Patients present with heterogeneous clinicopathological  
5 manifestations and variable prognosis, from asymptomatic changes in urinalysis to  
6 rapidly progressive glomerulonephritis (2). Up to 39% of patients progress to end-stage  
7 renal disease (ESRD) over 20 years of follow-up (3). Present treatments carry severe  
8 side-effects and largely fail to halt the progression of renal decline (4). The mainstay  
9 of therapy is optimized supportive care, i.e., measures that lower blood pressure,  
10 reduce proteinuria, minimize lifestyle risk factors, and otherwise help to reduce non-  
11 specific insults to the kidneys. The use of immunosuppression has become  
12 controversial because of its low effectiveness and high rate of serious side effects  
13 mainly associated with glucocorticoid treatment (5). However new treatment regimens  
14 with low dose steroids and enteral targeted-release budesonide for high-risk patients  
15 may decrease the rate of IgAN progression (6). Treatment advances in IgAN have  
16 been limited at least in part due to the incomplete understanding of disease  
17 aetiopathogenesis.

18 The multi-hit model of IgAN aetiopathogenesis proposes that IgAN is initiated with the  
19 overproduction of galactose-deficient IgA1 (Gd-IgA1), followed by the development of  
20 antibodies against pIgA1 (7-10). Together these form immune complexes that lead to  
21 nephrotoxicity through complement activation via alternative and lectin pathways. B  
22 cells are centrally implicated in the pathogenesis of IgAN as the source of  
23 hypoglycosylated IgA1 and autoantibodies against it (11, 12). Nevertheless, there are  
24 crucial gaps in the knowledge on B cell activation and differentiation pathways that  
25 lead to secretion of pathogenic IgA antibodies in IgAN. This is particularly striking when  
26 compared to the comprehensive understanding gained in other immune-mediated  
27 kidney diseases, particularly systemic lupus erythematosus (13-15).

28 Isolated reports have characterised distinct aspects of B cell activation in patients with  
29 IgAN. Among the reported B cell alterations have been the reduction in regulatory B  
30 cells (16), elevated toll-like receptor 7 (TLR7) expression in circulating B cells (17) and  
31 increased frequency of CCR9<sup>pos</sup>IgA<sup>pos</sup> B cells in blood (18). However, B cell activation  
32 pathways have not been investigated and remain to be integrated into the paradigm of  
33 IgAN aetiopathogenesis. Here we carry out peripheral B cell profiling in a biopsy-

1 confirmed cohort of IgAN patients and healthy controls (HC) to uncover B cell activation  
2 pathways that operate in IgAN as well as to determine the cellular pathways implicated  
3 in the secretion of pathogenic IgA.

#### 4 **Materials and Methods**

5 **Study participants.** Adults with biopsy-confirmed IgAN were recruited at the  
6 Nephrology Centre at Pauls Stradins Clinical University Hospital, Riga, Latvia between  
7 January 2020 and June 2022. This is the only centre for kidney diseases in Latvia,  
8 where IgAN is diagnosed in adults, therefore the IgAN patient cohort is representative  
9 of all Latvian adults with IgAN. Age- and sex-matched healthy volunteers were also  
10 enrolled. Healthy controls had age-appropriate kidney function, without active urine  
11 sediment and proteinuria. Individuals with diabetes mellitus, current pregnancy, severe  
12 organ dysfunction, acute cardiovascular disease, hepatic diseases, acute or chronic  
13 inflammatory, autoimmune or infectious diseases, immunodeficiency, malignancies,  
14 substance and alcohol abuse, kidney replacement therapy (including kidney  
15 transplantation) were excluded from the study. All participants provided written  
16 informed consent. This study was approved by the Clinical Research Ethics Committee  
17 of Pauls Stradins Clinical University Hospital (No 191219-6L) and was performed  
18 under the guidance of the Declaration of Helsinki.

19 **Clinical and laboratory characterisation.** Serum creatinine, albumin and total  
20 cholesterol were measured on Atellica CH (Siemens Healthineers, Erlangen,  
21 Germany). Estimated glomerular filtration rate (eGFR) was calculated using the CKD-  
22 EPI Creatinine Equation (2021). Serum IgA was measured on Atellica NEPH 630  
23 (Siemens Healthineers, Erlangen, Germany). Proteinuria was determined by spot  
24 protein-to-creatinine ratio. Assessment of protein in urine was performed on Cobas  
25 Integra 400 Plus (Roche Diagnostics GmbH, Mannheim, Germany). Red blood cell  
26 count in urine was determined on Atellica 1500 automated urinalysis system (Siemens  
27 Healthineers, Erlangen, Germany). The complete blood counts were performed on  
28 ethylenediaminetetraacetic acid (EDTA)-treated peripheral blood samples using  
29 UniCel DxH cellular analysis system (Beckman Coulter, Miami, FL, USA). Serum  
30 lipopolysaccharide (LPS) levels were detected by ELISA (MyBioSource MBS702450,  
31 San Diego, CA, USA) according to the manufacturer's instructions. Gd-IgA1 levels in  
32 serum were measured using an ELISA kit (Gd-IgA1 Assay Kit-IBL 30111694, IBL  
33 international GmbH, Germany) following the manufacturer's instructions. The samples

1 were diluted 200-fold using the provided EIA buffer to obtain biomarker levels within  
2 the measurement range of the kit (1.56-100 ng/mL). Blood pressure was measured by  
3 a physician during study recruitment.

#### 4 **Peripheral blood mononuclear cell (PBMC) isolation and serum collection.**

5 Peripheral blood was obtained from study participants. Serum from tubes with  
6 coagulation activator was isolated by centrifugation and was either used immediately  
7 or stored at -80C. PBMCs were isolated from heparinized blood by density gradient  
8 centrifugation using Histopaque-1077 (Sigma-Aldrich, St. Louis, USA). After washing  
9 with complete RPMI-1640 (10% fetal bovine serum and 1% penicillin-streptomycin in  
10 RPMI-1640), PBMCs were resuspended in freezing media (90% fetal bovine serum  
11 and 10% dimethyl sulfoxide) and cryopreserved. All laboratory analyses were done in  
12 the Joint Laboratory at Pauls Stradins Clinical University Hospital (Riga, Latvia).

#### 13 **Immunophenotyping of peripheral blood B cells by flow cytometry.**

14 Using antibodies against CD24, CD27, CD38 and IgD we were able to enumerate transitional  
15 (CD24<sup>hi</sup>CD38<sup>hi</sup>), mature naive (CD24<sup>int</sup>CD38<sup>int</sup>), activated (CD24<sup>lo</sup>CD38<sup>lo</sup>), and total  
16 memory (CD24<sup>hi</sup>CD38<sup>lo</sup>) B cells, including class-switched (IgD<sup>neg</sup>) and unswitched  
17 (IgD<sup>pos</sup>) subsets, double negative (IgD<sup>neg</sup>CD27<sup>neg</sup>) B cells, pre-plasmablasts  
18 (CD24<sup>lo</sup>CD38<sup>hi</sup>) and plasmablasts (CD27<sup>pos</sup>CD38<sup>hi</sup>). We further interrogated IgA,  
19 CD21, T-bet, Ki-67 expression in B cell subsets. Briefly, for PBMC viability LIVE/DEAD  
20 Fixable Near-IR Dead Cell Stain Kit was used (Invitrogen, MA, USA). Nonspecific  
21 staining was prevented with Fc receptor blocking reagent (Miltenyi Biotec, Bergisch  
22 Gladbach, Germany). The cells were incubated with antibodies (details see Suppl.  
23 Table 1) for 40 minutes at 4C, afterwards unbound antibodies were removed by two  
24 washes with flow cytometry staining buffer (2% fetal bovine serum and 2 mM EDTA in  
25 phosphate-buffered solution (PBS)) and fixed with PBS containing 2% formaldehyde.  
26 For intracellular and transcription factor staining, cells were fixed and permeabilized  
27 using the Foxp3/Transcription Factor Staining Buffer Set (00-5523-00, eBioscience)  
28 followed by incubation with antibodies diluted in permeabilization buffer for 50 minutes  
29 at 4C. Samples were acquired on the Navios EX flow cytometer (Beckman Coulter,  
30 Inc., Brea, CA, USA) and analysed with FlowJo software (BD Life Sciences). For the  
31 detection of GdIgA1 B cells, we stained PBMCs with a fluorophore labelled (R10712  
32 ReadyLabel™, Invitrogen, MA, USA) monoclonal antibody (Gd-IgA1 (KM55)-IBL  
33 30117066, IBL Japan, Japan) at 37C for 40 minutes. To further enumerate Gd-IgA1

1 plasmablasts, cells were fixed again permeabilized using the Foxp3/Transcription  
2 Factor Staining Buffer Set and then stained intracellularly with the Gd-IgA1 monoclonal  
3 antibody.

4 **Statistical analysis.** All the statistical analyses were conducted using GraphPad  
5 Prism 9 (La Jolla, CA, USA). Data distribution was assessed by the Shapiro-Wilk test  
6 and normal Q-Q plots. For normally distributed and homogenous data, independent  
7 samples t-test was used; when data were not normally distributed, Mann-Whitney U  
8 test was used. Fisher's exact test was used to compare sex between groups.  
9 Spearman's rank correlation test was used to interrogate statistical significance in  
10 correlations. Results were considered statistically significant at  $p < 0.05$ .

## 11 **Results**

12 To uncover B activation pathways and how peripheral B cell composition may be  
13 impacted in patients with IgAN, we recruited 36 patients with IgAN and 19 healthy  
14 controls (HCs). See Methods for full participant inclusion and exclusion criteria. The  
15 demographic, clinical and laboratory data of the cohort are summarised in Table 1.  
16 Study participants were sex- and age-matched. Both groups had normal and  
17 comparable leukocyte and lymphocyte counts. As expected, IgAN patients had higher  
18 serum creatinine levels and lower eGFR than HCs. IgAN patients represented all four  
19 CKD stages (from 1 to 4) based on eGFR. The median proteinuria of patients with  
20 IgAN was 0,48 g/g (IQR 0,26-1,35), 11 patients had moderate proteinuria (1-3g) and  
21 only one patient had nephrotic range proteinuria (>3g). According to the Oxford  
22 classification of IgAN (19), a frequent histological finding was secondary  
23 glomerulosclerosis (69,4%). Only in rare cases tubular atrophy or crescents in <25%  
24 of glomeruli were seen. Of note, BMI is associated with worse presentation and long-  
25 term outcome of IgAN (20, 21), and B cell activation pathways are dysregulated in  
26 obesity (22). In our cohort there were no significant differences in BMI between IgAN  
27 patients and controls.

28 We first carried out B cell phenotyping based on CD24, CD27, CD38 and IgD surface  
29 expression. This allowed us to enumerate transitional ( $CD24^{hi}CD38^{hi}$ ), mature naive  
30 ( $CD24^{int}CD38^{int}$ ), activated ( $CD24^{lo}CD38^{lo}$ ), and total memory ( $CD24^{hi}CD38^{lo}$ ) B cells,  
31 including class-switched ( $IgD^{neg}$ ) and unswitched ( $IgD^{pos}$ ) subsets, double negative  
32 ( $IgD^{neg}CD27^{neg}$ ) B cells, pre-plasmablasts ( $CD24^{lo}CD38^{hi}$ ) and plasmablasts  
33 ( $CD27^{pos}CD38^{hi}$ ). The CD24/CD38 gating strategy confirmation is shown in Suppl.

1 Figure 1. We found that IgAN patients had a significant increase in mature naive B  
2 cells with a reciprocal decrease in the frequency of total memory B cells (Figure 1a).  
3 Frequencies of switched and unswitched memory B cells were comparable (Figure  
4 1b). A novel population of IgD<sup>neg</sup>CD27<sup>neg</sup> B cells termed double negative (DN) or  
5 atypical memory B cells has been recently described. These DN B cells are expanded  
6 in autoimmune conditions, such as systemic lupus erythematosus (SLE), and  
7 especially in those with nephritis (14, 15). These cells have been shown to be the  
8 precursors of autoantibody-producing plasmablasts in SLE. Nevertheless, total double  
9 negative (DN) B cells and plasmablasts were comparable in patients with IgAN and  
10 HCs (Figure 1c).

11 The cellular origin and pathway that gives rise to IgA-producing B cells in IgAN is  
12 unknown, therefore, we next wanted to assay specifically IgA-expressing B cells and  
13 antibody-secreting cells (ASCs). That is, we wanted to know if systemic perturbations  
14 in the activation and differentiation of IgA-expressing B cells can be detected in patients  
15 with IgAN. Among B cells, IgA-expressing classical memory (CD27<sup>pos</sup>) B cell frequency  
16 was comparable between IgAN patients and HCs (Figure 2a). However, we noted that  
17 in addition to CD27-expressing B cells, there was a smaller population of IgA class-  
18 switched B cells that lacked CD27 expression, which was particularly pronounced in  
19 IgAN patients. Indeed, there was a significant expansion of these IgA-expressing  
20 CD27<sup>neg</sup> B cells in patients with IgAN (Figure 2a). We also detected a significantly  
21 higher frequency of IgA class-switched ASCs in IgAN patients compared to controls  
22 (Figure 2b). Supporting a lineage relationship between IgA-expressing plasmablasts  
23 and IgA-expressing CD27<sup>neg</sup> B cells, we found a correlation between these two subsets  
24 (Figure 2c).

25 We next wanted to address whether the IgA-expressing B cells were indeed  
26 expressing GdIgA1. We found that IgA<sup>pos</sup>CD27<sup>neg</sup> B cells co-expressed GdIgA1 (Figure  
27 2d). Reciprocally, in IgAN patients the majority of all GdIgA1<sup>+</sup> B cells were CD27<sup>neg</sup>  
28 (Figure 2e,f). IgA<sup>pos</sup> plasmablasts also expressed high levels of GdIgA1 (Figure 2g).  
29 Finally, implicating the IgA-expressing plasmablast as a potential functional contributor  
30 to pathogenesis, we observed a correlation between IgA<sup>pos</sup> plasmablasts and  
31 circulating IgA levels (Figure 2h). Nevertheless, despite the correlation between IgA  
32 and GdIgA1, we did not find a relationship between IgA<sup>pos</sup> plasmablasts and serum  
33 GdIgA1 levels (Figure 2i).



1 CD27<sup>neg</sup> antigen-experienced B cells comprise two subsets, termed double negative  
2 (DN) 1 and 2. DN1 cells are defined by their expression of CD21 and CXCR5, while  
3 DN2 B cells lack CD21 and CXCR5 expression and instead express CD11c and are  
4 transcriptionally regulated by T-bet (15). Based on their transcriptional signatures  
5 these two subsets of B cells arise from different activation pathways (15). While DN2  
6 B cells arise through extrafollicular B cell activation, DN1 B cells represent precursors  
7 of classical memory B cells that have recently emerged from the germinal centre  
8 reaction (and have not yet upregulated CD27). Of note, germinal centres are the  
9 microanatomical structures that allow the evolution (by somatic hypermutation of  
10 antibody-encoding genes) and selection (affinity maturation) of B cells that enable the  
11 production of high-affinity antibodies (23). The understanding of which pathway B cells  
12 are activated through can elucidate factors that regulate the response (e.g. T cell help)  
13 or properties of the compartment (e.g. longevity) (23). We found that the IgA<sup>neg</sup>CD27<sup>pos</sup>  
14 B cells were phenotypically CD21<sup>hi</sup> and T-bet<sup>lo</sup> corresponding to DN1 phenotype  
15 (Figure 3a), suggesting they may indeed be the precursors of IgA<sup>pos</sup>CD27<sup>pos</sup> classical  
16 memory B cells. Of note, we used IgA<sup>pos</sup>CD27<sup>pos</sup> memory B cells as a control for high  
17 expression of CD21 and lack of T-bet. To further interrogate this developmental  
18 relationship, we reasoned that most of the classical memory compartment (CD27<sup>pos</sup>)  
19 in patients with IgAN and HCs would be composed of foreign-antigen specific B cells  
20 generated throughout the lifetime. The vast majority of this pool should be resting cells,  
21 apart from those that report and participate in an on-going immune response. We then  
22 carried out Ki-67 staining and found a significant positive correlation between  
23 proliferating IgA<sup>pos</sup> DN1 and Ki-67<sup>pos</sup>IgA<sup>pos</sup>CD27<sup>pos</sup> memory B cells (Figure 3b).  
24 Therefore, the shared phenotypic and proliferation characteristics of these subsets  
25 suggest a developmental relationship and support increased generation of IgA-  
26 expressing ASCs through the germinal centre pathway.

27 Finally, we wanted to explore the mucosal-kidney axis in relation to B cell activation in  
28 IgAN and ask if previously reported perturbations at mucosal surfaces were linked to  
29 this DN1 B cell differentiation pathway. LPS is known to not only influence B cell class-  
30 switching to IgA (24, 25) but is also used as a surrogate marker of dysbiosis and gut  
31 permeability (26-29). We found that LPS was significantly elevated in the serum of  
32 IgAN patients compared to HCs (Figure 4a), confirming previously published data (30).  
33 We further found that IgA-expressing CD27<sup>neg</sup> B cells correlated with serum LPS levels  
34 (Figure 4b; the relationships between LPS and the other B cell subsets examined in

1 this study are presented in Suppl. Table 2). This suggests LPS may either directly drive  
2 their expansion/class-switching or that the observed correlation is because both  
3 increased LPS and IgA<sup>pos</sup>CD27<sup>neg</sup> B cells are a consequence of mucosal  
4 dysbiosis/reduced barrier function, which contributes to IgA-expressing plasmablast  
5 differentiation. Finally, we wanted to ask how the expansion of IgA<sup>pos</sup>CD27<sup>neg</sup> B cells  
6 related to clinical features of IgAN. We found that specifically in patients with reduced  
7 kidney function (eGFR <90mL/min) there was an inverse correlation between eGFR  
8 and the frequency of IgA<sup>pos</sup>CD27<sup>neg</sup> B cells (Figure 4c).

9

## 10 **Discussion**

11 The multi-hit model is the blueprint for explaining IgAN aetiopathogenesis (7-10).  
12 Advances have been made particularly in uncovering the mechanisms operating within  
13 the kidney that contribute to organ damage (hit 4, see Figure 5). These include the  
14 dissection of how immune complexes containing IgA bind to mesangial cells, triggering  
15 proliferation and increased synthesis of extracellular matrix components as well as the  
16 role of the CD89, the IgA Fc receptor, in regulating tissue damage (31, 32). However,  
17 these mechanistic insights are unlikely to provide the key to therapeutic advances as  
18 they operate once B cell tolerance is already broken.

19 We report here that global alterations in the B cell compartment are present in patients  
20 with IgAN, specifically the expansion of naive B cells and a reduction in total memory  
21 B cells. This observation is of significance as IgAN is considered an organ-specific  
22 autoimmune disease, yet these data support that systemic immunity is dysregulated  
23 beyond that which has been previously described at mucosal sites (33-35). Increase  
24 in naive B cells and reduction in total memory B cells is characteristic of systemic  
25 autoimmune diseases such as systemic lupus erythematosus (SLE) and conditions  
26 associated with chronic low-grade inflammation, including obesity (15, 22). However,  
27 we did not observe an expansion of total DN B cells associated with most severe  
28 systemic autoimmune and inflammatory phenotypes. It will be important to address  
29 whether the systemic changes in the overall B cell landscape we report here are causal  
30 to IgAN or a consequence of autoimmunity-associated inflammation/bystander effects.

31 As the source of pathogenic Gd-IgA1 antibodies, B cells are a promising target in IgAN,  
32 but B cell activation and differentiation pathways that lead to pathogenic IgA production

1 remain uncharacterised. Understanding how B cells are affected and become activated  
2 is thus important for the complete understanding of IgAN pathogenesis, prognosis, and  
3 treatment. Here we provide mechanistic insight into the early steps of IgAN  
4 aetiopathogenesis by uncovering that IgA-expressing B cells that lack the classical  
5 memory marker CD27 but express CD21 are expanded in patients with IgAN and  
6 appear to be the cellular precursors of IgA-producing plasmablasts. We show that such  
7 ASC precursors are apparently recent emigrants from on-going germinal centres,  
8 which suggests the continuous output of the pathogenic precursors, rather than  
9 dominant contribution by memory B cells and plasmablasts differentiated at an earlier  
10 timepoint. DN1 B cells have not been previously associated with disease states (unlike  
11 the extensively characterised DN2 subset) therefore, this work may help uncover more  
12 about this B cell population. This observation of increased recent germinal centre  
13 emigrant DN1 B cells also fits with the report of increased frequency of Tfh cells in  
14 IgAN patients (36).

15 That we found a correlation between the CD27<sup>neg</sup> precursors of IgA-expressing  
16 plasmablasts and serum LPS levels, implicates mucosal immunity in the differentiation  
17 of these cells. LPS could directly contribute to class-switching in activated B cells as  
18 previously observed (24, 25). In support of direct activation, tonsillar B cells from IgAN  
19 patients have been shown to produce increased IgA in response to LPS stimulation  
20 (37). Others have shown that upon in vitro culture with LPS, B cells downregulate the  
21 expression of  $\beta$ 3-galactosyltransferase-specific molecular chaperone (Cosmc) (38).  
22 Therefore, LPS may act at multiple stages of B cell activation to not only induce class-  
23 switching and IgA production, but to also regulate IgA glycosylation. Another possible  
24 explanation for the correlation between IgA<sup>pos</sup>CD27<sup>neg</sup> B cells and LPS is that both are  
25 increased as a consequence of intestinal inflammatory processes that may result in  
26 enhanced generation of IgA<sup>pos</sup>CD27<sup>neg</sup> B cells and increased intestinal permeability.  
27 Supporting the mucosa as a site of origin for these IgA-expressing B cells, IgAN  
28 patients have an increased frequency of IgA<sup>pos</sup> B cells that express the mucosal  
29 homing marker CCR9 (18). It is possible that tonsillectomy, a procedure that has  
30 demonstrated to be of some benefit in IgAN (39, 40), may eliminate the niche of either  
31 generation or homing of these B cells as has been speculated by others (41). It may  
32 also provide clues as to why B cell depletion has shown variable success in IgAN  
33 despite the central role of B cells in the disease pathogenesis (42)– the mucosal niches  
34 may harbour the majority of precursors that are not efficiently depleted by the B cell

1 targeting therapy. Albeit the literature is not consistent, studies have suggested that  
2 rituximab may be less effective in depleting B cells within lymphoid tissues (43). Recent  
3 findings of disease-modifying effects of enteral budesonide in IgAN further implicate  
4 mucosal sites in driving immunopathogenesis (44). Whether budesonide affects B cell  
5 phenotypes remains to be determined, but it is tempting to speculate that it indirectly  
6 targets IgA<sup>pos</sup> ASC precursors at mucosal sites. Additionally in other autoimmune  
7 diseases both memory B cells and B cells de novo engaging in immune responses –  
8 such as germinal centre B cells which are the proposed progenitors of DN1 B cells –  
9 have been shown to be resistant to rituximab treatment (45, 46).

10 In IgAN endocapillary proliferation, tubular atrophy/interstitial fibrosis are independent  
11 predictors of rate of loss of renal function (47). In our cohort of IgAN patients, the  
12 prevalence of these findings was relatively low. It is important to note that kidney biopsy  
13 may have been conducted several years before the patient's visit. The distribution of  
14 men, as well as the age and BMI, was found to be similar to that reported in other  
15 studies focusing on IgAN. Clinically, patients exhibited lower protein excretion, yet their  
16 eGFR was worse when compared to the results of other studies evaluating B cells in  
17 IgAN (16, 18). Of note, a limitation of the study is that our cohort consisted entirely of  
18 white Eastern Europeans and thus the B cell activation pathway we have uncovered  
19 remains to be investigated in non-European cohorts.

20 Now that we have identified the aberrant B cell differentiation pathways in IgAN,  
21 important further questions can be addressed. Due to their expression of GdIgA1, it is  
22 tempting to speculate that IgA<sup>pos</sup>CD27<sup>neg</sup> cells participate in disease precipitation,  
23 albeit this remains to be experimentally demonstrated. That is, the enhanced  
24 generation of IgA<sup>pos</sup>CD27<sup>neg</sup> precursors could drive disease or these cells may be  
25 generated as part of ongoing inflammation and not causal in IgAN development. Since  
26 this study aimed to capture the whole range of IgAN clinical features, our cohort  
27 comprised only 6 patients with eGFR>90mL/min. We speculate that if the B cell  
28 dysregulation we characterise here underlies disease, patients would present with an  
29 increased activation of this pathway prior to detectable decline in renal function. With  
30 regards to the antigen specificity and clonality of IgA-expressing B cells: what are the  
31 B cells recognising (e.g. food, microbial antigens) and how diverse is the IgA response  
32 within an individual and between individuals? With regards to the site of induction and  
33 long-term residence – where are the IgA-expressing plasmablast precursors induced

1 and maintained (e.g. mucosa, bone marrow) and is this shared across IgAN patients?  
2 How are pathogenic IgA<sup>pos</sup>CD27<sup>neg</sup> B cells different from foreign-antigen reactive  
3 IgA<sup>pos</sup>CD27<sup>pos</sup> B cells– can targets be identified to specifically deplete or inhibit the  
4 differentiation of pathogenic B cells?

5 In summary, we propose that dysregulation of mucosal immunity may drive the  
6 increased naïve B cell activation in germinal centres, giving rise to  
7 IgA<sup>pos</sup>CD27<sup>neg</sup>CD21<sup>pos</sup> B cells and subsequently IgA-producing plasmablasts; this  
8 pathway can be further explored for biomarkers and therapeutic targets in IgAN.

9 **Data availability statement:**

10 The data that support the findings of this study are available in the article and in its  
11 online supplementary material.

12 **Acknowledgements:**

13 We thank Dr Elizabeth C. Rosser for critically reviewing the manuscript and all the  
14 study participants, who made this research possible.

15 **Funding:**

16 This work was funded by the Latvian Council of Science, project Nr. Izp-2019/1-0139.

17 **Authors' contributions:**

18 AP, KR, VK, JK, AL, KO designed the study; AP, KR, VK, HC, AP were responsible for  
19 patient and control group selection and enrolment; AP, KR, VK, MS, JS, AJS, AV  
20 collected patient medical histories, obtained patient samples; AP, BS, KR, VK, RK,  
21 MS, JS, AJS, AV, KV, DP, JK, HC, AL, AP, KO conducted experiments and analysed  
22 data; KO and RK interpreted results, wrote and revised the manuscript and all authors  
23 contributed to the final manuscript.

24 **Conflict of interest statement:**

25 The authors declare that the research was conducted in the absence of any  
26 commercial or financial relationships that could be construed as a potential conflict of  
27 interest.

28  
29  
30  
31  
32

1 **References:**

- 2 1. McGrogan A, Franssen CF, de Vries CS. The incidence of primary  
3 glomerulonephritis worldwide: a systematic review of the literature. *Nephrol Dial*  
4 *Transplant.* 2011;26(2):414-30.
- 5 2. Lafayette RA, Kelepouris E. Immunoglobulin A Nephropathy: Advances in  
6 Understanding of Pathogenesis and Treatment. *Am J Nephrol.* 2018;47 Suppl 1:43-  
7 52.
- 8 3. Berthoux FC, Mohey H, Afiani A. Natural history of primary IgA nephropathy.  
9 *Semin Nephrol.* 2008;28(1):4-9.
- 10 4. Gleeson PJ, O'Shaughnessy MM, Barratt J. IgA nephropathy in adults -  
11 Treatment Standard. *Nephrol Dial Transplant.* 2023.
- 12 5. Ponticelli C, Locatelli F. Corticosteroids in IgA Nephropathy. *Am J Kidney Dis.*  
13 2018;71(2):160-2.
- 14 6. Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy. *Semin*  
15 *Immunopathol.* 2021;43(5):717-28.
- 16 7. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The  
17 pathophysiology of IgA nephropathy. *J Am Soc Nephrol.* 2011;22(10):1795-803.
- 18 8. Magistroni R, D'Agati VD, Appel GB, Kiryluk K. New developments in the  
19 genetics, pathogenesis, and therapy of IgA nephropathy. *Kidney Int.* 2015;88(5):974-  
20 89.
- 21 9. Gentile M, Sanchez-Russo L, Riella LV, Verlato A, Manrique J, Granata S, et al.  
22 Immune abnormalities in IgA nephropathy. *Clin Kidney J.* 2023;16(7):1059-70.
- 23 10. Wyatt RJ, Julian BA. IgA nephropathy. *N Engl J Med.* 2013;368(25):2402-14.
- 24 11. Novak J, Julian BA, Tomana M, Mestecky J. IgA glycosylation and IgA immune  
25 complexes in the pathogenesis of IgA nephropathy. *Semin Nephrol.* 2008;28(1):78-87.
- 26 12. Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, et al.  
27 Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.  
28 *Kidney Int.* 2007;71(11):1148-54.

- 1 13. Oleinika K, Mauri C, Salama AD. Effector and regulatory B cells in immune-  
2 mediated kidney disease. *Nat Rev Nephrol*. 2019;15(1):11-26.
- 3 14. Tipton CM, Fucile CF, Darce J, Chida A, Ichikawa T, Gregoret I, et al. Diversity,  
4 cellular origin and autoreactivity of antibody-secreting cell population expansions in  
5 acute systemic lupus erythematosus. *Nat Immunol*. 2015;16(7):755-65.
- 6 15. Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al.  
7 Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to  
8 Pathogenic Responses in Systemic Lupus Erythematosus. *Immunity*. 2018;49(4):725-  
9 39 e6.
- 10 16. Wang YY, Zhang L, Zhao PW, Ma L, Li C, Zou HB, et al. Functional implications  
11 of regulatory B cells in human IgA nephropathy. *Scand J Immunol*. 2014;79(1):51-60.
- 12 17. Sendic S, Mansouri L, Lundberg S, Nopp A, Jacobson SH, Lundahl J. B cell and  
13 monocyte phenotyping: A quick asset to investigate the immune status in patients with  
14 IgA nephropathy. *PLoS One*. 2021;16(3):e0248056.
- 15 18. Sallustio F, Curci C, Chaoul N, Fonto G, Lauriero G, Picerno A, et al. High levels  
16 of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of  
17 intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients.  
18 *Nephrol Dial Transplant*. 2021;36(3):452-64.
- 19 19. Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford  
20 Classification of IgA nephropathy 2016: an update from the IgA Nephropathy  
21 Classification Working Group. *Kidney Int*. 2017;91(5):1014-21.
- 22 20. Kataoka H, Ohara M, Shibui K, Sato M, Suzuki T, Amemiya N, et al. Overweight  
23 and obesity accelerate the progression of IgA nephropathy: prognostic utility of a  
24 combination of BMI and histopathological parameters. *Clin Exp Nephrol*.  
25 2012;16(5):706-12.
- 26 21. Hong YA, Min JW, Ha MA, Koh ES, Kim HD, Ban TH, et al. The Impact of  
27 Obesity on the Severity of Clinicopathologic Parameters in Patients with IgA  
28 Nephropathy. *J Clin Med*. 2020;9(9).
- 29 22. Slisere B, Arisova M, Aizbalte O, Salmina MM, Zolovs M, Levensteins M, et al.  
30 Distinct B cell profiles characterise healthy weight and obesity pre- and post-bariatric  
31 surgery. *Int J Obes (Lond)*. 2023;47(10):970-8.

- 1 23. Elsner RA, Shlomchik MJ. Germinal Center and Extrafollicular B Cell  
2 Responses in Vaccination, Immunity, and Autoimmunity. *Immunity*. 2020;53(6):1136-  
3 50.
- 4 24. Stavnezer J, Guikema JE, Schrader CE. Mechanism and regulation of class  
5 switch recombination. *Annu Rev Immunol*. 2008;26:261-92.
- 6 25. Cerutti A. The regulation of IgA class switching. *Nat Rev Immunol*.  
7 2008;8(6):421-34.
- 8 26. Scaldaferri F, Lopetuso LR, Petito V, Cufino V, Bilotta M, Arena V, et al. Gelatin  
9 tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating  
10 gut microbiota composition: Emerging role for 'gut barrier protectors' in IBD? *United*  
11 *European Gastroenterol J*. 2014;2(2):113-22.
- 12 27. Zhao H, Zhang H, Wu H, Li H, Liu L, Guo J, et al. Protective role of 1,25(OH)<sub>2</sub>  
13 vitamin D<sub>3</sub> in the mucosal injury and epithelial barrier disruption in DSS-induced acute  
14 colitis in mice. *BMC Gastroenterol*. 2012;12:57.
- 15 28. Yu LC, Flynn AN, Turner JR, Buret AG. SGLT-1-mediated glucose uptake  
16 protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: a  
17 novel cellular rescue mechanism? *FASEB J*. 2005;19(13):1822-35.
- 18 29. Nighot M, Al-Sadi R, Guo S, Rawat M, Nighot P, Watterson MD, et al.  
19 Lipopolysaccharide-Induced Increase in Intestinal Epithelial Tight Permeability Is  
20 Mediated by Toll-Like Receptor 4/Myeloid Differentiation Primary Response 88  
21 (MyD88) Activation of Myosin Light Chain Kinase Expression. *Am J Pathol*.  
22 2017;187(12):2698-710.
- 23 30. Tang Y, Zhu Y, He H, Peng Y, Hu P, Wu J, et al. Gut Dysbiosis and Intestinal  
24 Barrier Dysfunction Promotes IgA Nephropathy by Increasing the Production of Gd-  
25 IgA1. *Front Med (Lausanne)*. 2022;9:944027.
- 26 31. Launay P, Grossetete B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L,  
27 et al. Fcα receptor (CD89) mediates the development of immunoglobulin A (IgA)  
28 nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-IgA  
29 complexes in patients and CD89 transgenic mice. *J Exp Med*. 2000;191(11):1999-  
30 2009.



- 1 32. Van der Steen LP, Bakema JE, Sesarman A, Florea F, Tuk CW, Kirtschig G, et  
2 al. Blocking Fc $\alpha$ 1 receptor I on granulocytes prevents tissue damage induced by  
3 IgA autoantibodies. *J Immunol*. 2012;189(4):1594-601.
- 4 33. Bene MC, Hurault De Ligny B, Kessler M, Faure GC. Confirmation of tonsillar  
5 anomalies in IgA nephropathy: a multicenter study. *Nephron*. 1991;58(4):425-8.
- 6 34. Sugiyama N, Shimizu J, Nakamura M, Kiri T, Matsuoka K, Masuda Y.  
7 Clinicopathological study of the effectiveness of tonsillectomy in IgA nephropathy  
8 accompanied by chronic tonsillitis. *Acta Otolaryngol Suppl*. 1993;508:43-8.
- 9 35. Harper SJ, Allen AC, Bene MC, Pringle JH, Faure G, Lauder I, et al. Increased  
10 dimeric IgA-producing B cells in tonsils in IgA nephropathy determined by in situ  
11 hybridization for J chain mRNA. *Clin Exp Immunol*. 1995;101(3):442-8.
- 12 36. Zhang L, Wang Y, Shi X, Zou H, Jiang Y. A higher frequency of  
13 CD4(+)CXCR5(+) T follicular helper cells in patients with newly diagnosed IgA  
14 nephropathy. *Immunol Lett*. 2014;158(1-2):101-8.
- 15 37. Liu H, Peng Y, Liu F, Xiao W, Zhang Y, Li W. Expression of IgA class switching  
16 gene in tonsillar mononuclear cells in patients with IgA nephropathy. *Inflamm Res*.  
17 2011;60(9):869-78
- 18 38. Qin W, Zhong X, Fan JM, Zhang YJ, Liu XR, Ma XY. External suppression  
19 causes the low expression of the Cosmc gene in IgA nephropathy. *Nephrol Dial*  
20 *Transplant*. 2008;23(5):1608-14.
- 21 39. Hirano K, Matsuzaki K, Yasuda T, Nishikawa M, Yasuda Y, Koike K, et al.  
22 Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A  
23 Nephropathy. *JAMA Netw Open*. 2019;2(5):e194772.
- 24 40. Feriozzi S, Polci R. The role of tonsillectomy in IgA nephropathy. *J Nephrol*.  
25 2016;29(1):13-9.
- 26 41. Wu G, Peng YM, Liu FY, Xu D, Liu C. The role of memory B cell in tonsil and  
27 peripheral blood in the clinical progression of IgA nephropathy. *Hum Immunol*.  
28 2013;74(6):708-12.

- 1 42. Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A  
2 Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and  
3 Renal Dysfunction. *J Am Soc Nephrol*. 2017;28(4):1306-13.
- 4 43. Otten HG, Hans, Kyra, ten M, Leo, Hilbrands LB. A Single Dose of Rituximab  
5 Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and  
6 Function. *American Journal of Transplantation*. 2013 Jun 1;13(6):1503–11.
- 7 44. Lafayette R, Kristensen J, Stone A, Floege J, Tesar V, Trimarchi H, et al.  
8 Efficacy and safety of a targeted-release formulation of budesonide in patients with  
9 primary IgA nephropathy (NeflgArd): 2-year results from a randomised phase 3 trial.  
10 *Lancet*. 2023;402(10405):859-70.
- 11 45. Etienne Crickx, Pascal Chappert, Sokal A, Weller S, Imane Azzaoui,  
12 Vandenberghe A, et al. Rituximab-resistant splenic memory B cells and newly engaged  
13 naive B cells fuel relapses in patients with immune thrombocytopenia. *Science*  
14 *Translational Medicine*. 2021 Apr 14;13(589).
- 15 46. Jiang R, Fichtner ML, Hoehn KB, Pham MC, Stathopoulos P, Nowak RJ, et al.  
16 Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia  
17 gravis relapses. *JCI Insight*. 2020 Jul 23;5(14).
- 18 47. Chakera A, MacEwen C, Bellur SS, Chompuk LO, Lunn D, Roberts ISD.  
19 Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no  
20 immunosuppression. *J Nephrol*. 2016;29(3):367-75.

21

## 22 **Tables + table legends:**

23 **Table 1.** Demographic, clinical and laboratory characteristics of the study cohort  
24 (median, minimum-maximum, IQR).

25

## 26 **Figures + figure legends:**

27 **Figure 1.** IgAN-associated changes in the peripheral B cell landscape. Representative  
28 flow cytometry plots and summary bar charts demonstrating (a) the frequencies of  
29 transitional (CD24<sup>hi</sup>CD38<sup>hi</sup>), mature (CD24<sup>int</sup>CD38<sup>int</sup>), memory (CD24<sup>hi</sup>CD38<sup>lo</sup>), and  
30 activated B cells (CD24<sup>lo</sup>CD38<sup>lo</sup>) and pre-plasmablasts (CD24<sup>lo</sup>CD38<sup>hi</sup>), (b) the

1 distribution of memory B cells into IgD<sup>pos</sup> unswitched and IgD<sup>neg</sup> class-switched  
2 subsets, (c) the frequencies of total double negative (DN; IgD<sup>neg</sup>CD27<sup>neg</sup>) B cells and  
3 plasmablasts (CD27<sup>pos</sup>CD38<sup>hi</sup>) in IgAN patients and healthy controls. Data are  
4 mean±SD and each circle/square represents a study participant. For normally  
5 distributed CD24<sup>int</sup>CD38<sup>int</sup>, CD24<sup>hi</sup>CD38<sup>lo</sup>, IgD<sup>pos</sup> memory and IgD<sup>neg</sup> memory B cell  
6 populations independent samples t test was used to compare IgAN patients and  
7 healthy controls. For non-normally distributed CD24<sup>hi</sup>CD38<sup>hi</sup>, CD24<sup>lo</sup>CD38<sup>lo</sup>,  
8 CD24<sup>lo</sup>CD38<sup>hi</sup>, IgD<sup>neg</sup>CD27<sup>neg</sup> and CD27<sup>pos</sup>CD38<sup>hi</sup> B cell subsets Mann-Whitney U test  
9 was used for the comparison of IgAN patients and HCs.

10

11 **Figure 2.** Enhanced differentiation of IgA<sup>pos</sup>CD27<sup>neg</sup> B cells and IgA<sup>pos</sup> plasmablasts in  
12 IgAN. Representative flow cytometry plots and summary bar charts demonstrating the  
13 frequencies of (a) IgA<sup>pos</sup>CD27<sup>pos</sup> and IgA<sup>pos</sup>CD27<sup>neg</sup> B cells and (b) IgA<sup>pos</sup>  
14 plasmablasts, (c) linear regression analysis of IgA<sup>pos</sup>CD27<sup>neg</sup> B cells versus IgA<sup>pos</sup>  
15 plasmablasts, (d) representative flow cytometry histograms and summary bar charts  
16 demonstrating the median fluorescence intensity of GdIgA1 in IgA<sup>pos</sup> and IgA<sup>neg</sup>  
17 CD19<sup>pos</sup>CD27<sup>neg</sup> B cells, (e, f) representative flow cytometry plots and summary bar  
18 charts demonstrating the frequencies of (e) GdIgA1<sup>pos</sup> B cells and (f) the distribution of  
19 GdIgA1<sup>pos</sup> B cells into CD27<sup>neg</sup> and CD27<sup>pos</sup> subsets, (g) representative flow cytometry  
20 histograms and summary bar charts demonstrating the median fluorescence intensity  
21 of GdIgA1 in IgA<sup>pos</sup> and IgA<sup>neg</sup> plasmablasts, (h, i) linear regression analysis of (h)  
22 serum IgA levels versus IgA<sup>pos</sup> plasmablasts and (i) serum GdIgA1 versus serum IgA  
23 levels in IgAN patients and healthy controls. Data are mean±SD and each circle/square  
24 represents a study participant. For non-normally distributed subsets Mann-Whitney U  
25 test was used for the comparison of IgAN patients and HCs. Spearman's rank  
26 correlation tests were used to interrogate statistical significance in the correlation  
27 between IgA<sup>pos</sup>CD27<sup>neg</sup> B cells and IgA<sup>pos</sup> plasmablasts, serum IgA levels and IgA<sup>pos</sup>  
28 plasmablasts and serum GdIgA1 and serum IgA levels in IgAN patients and HCs.

29

30 **Figure 3.** IgA<sup>pos</sup>CD27<sup>neg</sup> B cells are phenotypically CD21<sup>+</sup>T-bet<sup>+</sup>. Representative flow  
31 cytometry histograms and summary bar charts demonstrating the median fluorescence  
32 intensity of CD21 (a) and T-bet (b) in IgA<sup>pos</sup>CD27<sup>neg</sup> and IgA<sup>pos</sup>CD27<sup>pos</sup> B cells, (c)  
33 representative flow cytometry plots and linear regression analysis of Ki-

1  $67^{\text{pos}}\text{IgA}^{\text{pos}}\text{CD27}^{\text{pos}}$  B cells versus  $\text{Ki-67}^{\text{pos}}\text{IgA}^{\text{pos}}\text{CD27}^{\text{neg}}$  B cells in HCs and IgAN  
2 patients. Data are mean $\pm$ SD and each circle/square represents a study participant. For  
3 non-normally distributed CD21 and T-bet MFI Mann-Whitney U test was used for the  
4 comparison of IgAN patients and healthy controls. Spearman's rank correlation test  
5 was used to interrogate statistical significance in correlations between Ki-  
6  $67^{\text{pos}}\text{IgA}^{\text{pos}}\text{CD27}^{\text{pos}}$  B cells and  $\text{Ki-67}^{\text{pos}}\text{IgA}^{\text{pos}}\text{CD27}^{\text{neg}}$  B cells in IgAN patients and HCs.

7




8 **Figure 4.** Serum LPS levels correlate with  $\text{IgA}^{\text{pos}}\text{CD27}^{\text{neg}}$  B cell frequency. (a)  
9 Summary bar chart showing serum LPS levels and (b) linear regression analysis of  
10 serum LPS levels versus  $\text{IgA}^{\text{pos}}\text{CD27}^{\text{neg}}$  B cells in IgAN patients and HCs. (c) Linear  
11 regression analysis of eGFR versus  $\text{IgA}^{\text{pos}}\text{CD27}^{\text{neg}}$  B cells in IgAN patients. Data are  
12 mean $\pm$ SD and each circle/square represents a study participant. For non-normally  
13 distributed serum LPS levels Mann-Whitney U test was used for the comparison of  
14 IgAN patients and healthy controls. Spearman's rank correlation test was used to  
15 interrogate statistical significance in the correlation between serum LPS levels and  
16  $\text{IgA}^{\text{pos}}\text{CD27}^{\text{neg}}$  B cells in IgAN patients and HCs.


17


18 **Figure 5.** Revised multi-hit model with integration of B cell activation pathways. Hit 1  
19 of the multi-hit pathogenesis is the production of pathogenic galactose-deficient IgA1  
20 (Gd-IgA1). This is followed by production of anti-IgA antibodies (Hit 2) and formation  
21 of immune complexes (Hit 3), which are finally deposited in the kidney glomeruli and  
22 cause tissue damage and renal decline. Here we have uncovered the B cell pathway  
23 that leads to Gd-IgA1 production (hit 1) in IgAN pathogenesis, and term it 'hit 0'.  
24 Specifically, naive B cells are de novo activated within germinal centers and give rise  
25 to  $\text{IgA}^{\text{pos}}\text{CD27}^{\text{neg}}$  DN1 B cells and subsequently IgA-expressing plasmablasts which  
26 secrete pathogenic IgA.

**Table 1.** Demographic, clinical and laboratory characteristics of the cohort.

<b>Baseline characteristics</b>	<b>HC, n = 19</b>	<b>IgAN patients, n = 36</b>	<b>p-value</b>
Age, yr	49 (23-66, IQR 38-53)	44,5 (22-65, IQR 37-50)	0,906
Male	13 (68,4%)	23 (63,9%)	0,775
BMI, kg/m <sup>2</sup>	26,8 (17,82-40,63, IQR 23,4-31,1)	25,5 (17,6-44,1, IQR 23,4-29,4)	0,816
Systolic BP, mmHg	122 (98-145, IQR 120-129)	139 (120-174, IQR 130-152)	<0,001
Diastolic BP, mmHg	80 (60-98, IQR 74-85)	85 (70-110, IQR 80-95)	0,024
Serum creatinine, $\mu$ mol/l	83 (55-102, IQR 74-87)	126,5 (49-402, IQR 95,5-214)	<0,001
eGFR, ml/min per 1,73m <sup>2</sup>	100 (70-128, IQR 96-107)	56 (15-131, IQR 25,5-85,5)	<0,001
CKD stage 1		6 (16,7%)	
CKD stage 2		12 (33,3%)	
CKD stage 3		7 (19,4%)	
CKD stage 4		11 (30,6%)	
Proteinuria, g/g		0,48 (0,07-6,18, IQR 0,26-1,35)	
Hematuria, RBC/ $\mu$ l		21,17 (0-1421, IQR 10-65)	
Serum albumin, g/l		46 (29-51, IQR 42,5-48)	
Serum total cholesterol, mmol/l		5,46 (3,79-8,11, IQR 4,94-5,9)	
Absolute leukocyte count, 10 <sup>9</sup> /l	5,3 (4,1-8,4, IQR 4,4-6,5)	7,15 (4,2-12,8, IQR 5,8-7,5)	0,07
Absolute lymphocyte count, 10 <sup>9</sup> /l	1,9 (1,4-3,0, IQR 1,8-2,4)	1,8 (0,9-3,1, IQR 1,5-2,2)	0,291
<b>Oxford classification</b>			
M1		29 (80,6%)	
E1		1 (2,8%)	
S1		25 (69,4%)	
T1		2 (5,6%)	
T2		2 (5,6%)	
C1		2 (5,6%)	














# Hit 0



# Hit 1



# Hit 2



# Hit 3



# Hit 4

